Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.52 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.49 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | OSBP | P22059 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.46 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.44 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 2/20 | 0.43 |
| ▸ | UGCG | Q16739 | 2/20 | 0.43 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16509068 | 0.95 | POLA1 (0.53) | POLA1CYP46A1PLA2G2AUSP2LMNA | |
| SCHEMBL16509072 | 0.93 | POLA1 (0.52) | POLA1CYP46A1PLA2G2AUSP2LMNA | |
| SCHEMBL13363986 | 0.89 | POLA1 (0.54) | POLA1CYP46A1PLA2G2AUSP2LMNA | |
| SCHEMBL13363898 | 0.89 | CYP46A1 (0.54) | POLA1CYP46A1PLA2G2AUSP2LMNA | |
| SCHEMBL13363867 | 0.88 | POLA1 (0.53) | POLA1CYP46A1PLA2G2AUSP2LMNA | |
| SCHEMBL13363953 | 0.87 | POLA1 (0.56) | POLA1CYP46A1PLA2G2AUSP2LMNA | |
| SCHEMBL16508962 | 0.86 | POLA1 (0.53) | POLA1CYP46A1PLA2G2AUSP2LMNA | |
| SCHEMBL16501501 | 0.86 | POLA1 (0.54) | POLA1CYP46A1PLA2G2AUSP2LMNA | |
| SCHEMBL13363961 | 0.85 | POLA1 (0.55) | POLA1CYP46A1PLA2G2AUSP2LMNA | |
| SCHEMBL13363899 | 0.85 | POLA1 (0.55) | POLA1CYP46A1PLA2G2AUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110305769-A1 | BRANCHED CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM | ENZON PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| WO-2010056403-A1 | BRANCHED CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM | ENZON PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110305769-A1 | BRANCHED CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM | NPC1L1, CETP, SREBF2 | POLA1 1271/4885CYP46A1 55/4885PLA2G2A 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.